Narnatumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Mouse |
Target | MST1R (aka RON) |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6454H10026N1754O2020S44 |
Molar mass | 145922.10 g·mol−1 |
![]() ![]() |
Narnatumab is a human monoclonal antibody designed for the treatment of cancer.[1] Clinical development was abandoned after phase I trials.[2]
Narnatumab was developed by ImClone Systems.
References[]
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab" (PDF). American Medical Association.
- ^ "Narnatumumab". AdisInsight. Retrieved 31 January 2017.
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibodies
- Abandoned drugs
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs